AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Codexis, Inc.
Video analysis: CDXS
All videosNo video analysis for this stock yet. Request one from our team.
News: CDXS
BlackRock Inc. Makes New Investment in Codexis, Inc. $CDXS
BlackRock Inc. bought a new stake in shares of Codexis, Inc. (NASDAQ: CDXS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,284,352 shares of the biotechnology company's stock, valued at approximately $16,463,000. BlackRock Inc. owned 8.01% of Codexis as of its most recent
Codexis to Participate in Cantor Global Healthcare Conference 2026
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
Codexis Q2 Earnings Call Highlights
Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
Codexis Reports Second Quarter 2026 Financial Results
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the appointment of David Butler, PhD, to its Strategic Advisory Board (SAB).
Similar companies
-
OmniAb, Inc.
OABI
·
NASDAQ
Compare
-
Insight Molecular Diagnostics Inc.
IMDX
·
NASDAQ
Compare
-
C4 Therapeutics, Inc.
CCCC
·
NASDAQ
Compare
-
Rani Therapeutics Holdings, Inc.
RANI
·
NASDAQ
Compare
-
Armata Pharmaceuticals, Inc.
ARMP
·
New York Stock Exchange Arca
Compare
-
Innate Pharma S.A.
IPHA
·
NASDAQ
Compare